GSK plc (GSK) announced that it has signed an agreement with Massachusetts-based biopharmaceutical company Boston Pharmaceuticals to acquire the latter’s lead pipeline drug, efimosfermin alfa.Efimosfermin is an investigational long-acting variant of FGF21 protein designed to treat and prevent the progression of steatotic liver disease (SLD), commonly known as fatty liver disease. Boston Pharma is currently evaluating the drug in mid-stage studies for metabolic dysfunction-associated steatohepatitis (MASH), ...